 I. To conduct a phase I dose escalation trial, to determine the safety and the maximum tolerated dose MTD, of oral po IPdR ropidoxuridine given daily for 28 consecutive days with concurrent intensity-modulated radiation therapy IMRT in patients with advanced gastrointestinal cancers treated with palliative radiation. 